Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by itching that affects 10% of adults in the United States.1 Advances in the pathogenesis of AD have elucidated a predominant Th2-associated immunopathogenesis pathway with interleukin (IL)-4 and IL-13 acting as key players. This is underscored by the success of dupilumab, which is a monoclonal antibody that blocks the IL-4 receptor α subunit, inhibiting the action of both IL-4 and IL-13 for the treatment of AD.2,3

Topics & Concepts